EUVIMEDEUVIMED entdecken
Crossref

QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis

Theodoros Tsampras, Alexios S Antonopoulos, Freideriki-Eleni Kourti, Konstantinos Tsioufis, Charalambos Vlachopoulos

Clinical Research in Cardiology · 2026

DOI: 10.1007/s00392-025-02680-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Theodoros Tsampras und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiogenetics Unit, 1 st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, 114 Vas. Sofias Avenue, Athen…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Electrocardiography, Cardiomyopathies, Long QT Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transthyretin amyloidosis is a significant cause of heart failure with an unfavorable prognosis. In recent years, diagnosing the disease has become easier, with most patients now diagnosed non-invasively, and tissue biopsy being required only in a minority of cases. Although various laboratory findings have been reported as transthyretin amyloidosis red flags, the diagnostic and prognostic value of various electrocardiogram parameters remain largely unknown. In this study, the significance of QTc interval prolongation in transthyretin cardiac amyloidosis patients was investigated. We retrospectively analyzed electrocardiogram data from n = 58 patients with transthyretin amyloid cardiomyopathy and compared them with distinct cohorts of patients diagnosed with other forms of heart muscle disease, i.e., hypertrophic cardiomyopathy and dilated cardiomyopathy. QTc prolongation was found to be a unique feature of transthyretin cardiac amyloidosis, not shared by other cardiomyopathy types. Increased QTc interval in transthyretin amyloidosis patients correlates with disease severity markers, including NYHA class, NAC stage, NT-proBNP, and troponin I levels, suggesting its potential as a unique biomarker for monitoring disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialElectrocardiographyCardiomyopathiesLong QT SyndromeHumansMaleFemaleRetrospective StudiesAgedMiddle AgedBiomarkersDisease ProgressionPrognosisSeverity of Illness IndexNatriuretic Peptide, BrainAged, 80 and overTroponin I

Stichwörter der Autor:innen

ElectrocardiogramQTc intervalQTc prolongationTransthyretin amyloidosis

Substanzen

BiomarkersNatriuretic Peptide, BrainTroponin I

Autor:innen und Institutionen

  • Cardiogenetics Unit, 1 st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, 114 Vas. Sofias Avenue, Athens, Greece.
  • Cardiogenetics Unit, 1 st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, 114 Vas. Sofias Avenue, Athens, Greece. cvlachop@otenet.gr.

Zitieren

APA

Tsampras, T., Antonopoulos, A. S., Kourti, F. E., Tsioufis, K., & Vlachopoulos, C. (2026). QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02680-x

Vancouver

Tsampras T, Antonopoulos AS, Kourti FE, Tsioufis K, Vlachopoulos C. QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02680-x

BibTeX
@article{Tsampras2026,
  author = {Tsampras, Theodoros and Antonopoulos, Alexios S and Kourti, Freideriki-Eleni and Tsioufis, Konstantinos and Vlachopoulos, Charalambos},
  title = {QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-025-02680-x}
}
Kostenlos starten →